NEW YORK (AP) ¿ Medical-technology company Delcath Systems Inc. said Tuesday the Food and Drug Administration granted its drug candidate melphalan an additional special designation. The agency gave the company "orphan drug" status for melphalan as a treatment for cancer affecting the body's neuroendocrine system. The in-development drug already has the special designation for two other potential uses in treating cancer. The drug candidate is in midstage development. Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. The incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits. Shares of New York-based Delcath rose 36 cents, or nearly 10 percent, to $4 in premarket trading.
More from Food & Drink
Boston Beer Gets Another Upgrade on Strong Growth of Truly Brand
Boston Beer receives another upgrade, this time from Citi analyst Wendy Nicholson, who boosts her rating on the stock to buy from neutral amid what she sees as 'terrific' growth of its hard seltzer brand, Truly.
Hormel Foods Is Still Attractive With a New Technical Strategy
Let's check out the charts and indicators again on HRL.
Why Hormel Foods CEO Isn't Worried About a Recession
Looking to try some pumpkin spice spam? Hormel Food CEO weighs in on the millennial, pumpkin-spice Spam and why he's not worried about a recession.
Domino's Analysts, Post-Earnings: Things Could Get Worse. Here's What to Weigh.
When considering Domino's stock, investors must study two key matters. One's negative, the other positive.